MedWatch

Analyst: Genmab's progress with the FDA sends a positive signal

It's not surprising that the US FDA has accepted Genmab's application for the drug tisotumab vedotin, but it's a feather in the company's cap that the application received priority review status.

Photo: Joost Melis / Genmab / PR

Genmab will probably manage better than the general stock market on Monday following the firm's Friday announcement that the US Food and Drug Administration (FDA) has accepted treating its – and Seagen's – biologics license application for the drug tisotumab vedotin in the US.

This is the view of Senior Equity Analyst at Danish bank Sydbank Søren Løntoft Hansen on this drug for treating recurrent or metastatic cervical cancer.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs